NCT05383547

Bortezomib for Treating Glomerular Diseases

Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney. Literature has reported that bortezomib can achieve a complete response rate of up to 38% in the treatment of glomerular diseases, but its safety and effectiveness remain to be assessed for the Chinese demographic. This study attempts to explore a new treatment plan for glomerular disease by observing the therapeutic effect of bortezomib on glomerular disease.

Conditions

• Bortezomib
• Glomerulonephritis
• MN
• MPGN
• FSGS
• IgA Nephropathy

Interventions

Type	Name	Description
DRUG	Bortezomib	Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.

Timeline

• Start date: 2022-08-02
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-05-20
• Last updated: 2022-10-31

Locations

1 site across 1 country: China